Arena Says Patient Programs Will Offset Belviq’s Premium Price For Some
This article was originally published in The Pink Sheet Daily
Executive Summary
The obesity pill will be priced at a slight premium to Vivus’ rival drug Qsymia, but Arena CEO says the amount patients will actually pay will vary based on coupon and rebate programs.
You may also be interested in...
Vivus Beefs Up Qsymia Efforts As Eisai Prepares To Launch Belviq
The obesity drug market will see substantial commercial investment in the second half of 2013. Vivus is planning its first DTC advertising for Qsymia and continuing its search for a big pharma partner, while Eisai/Arena have been cleared by the Drug Enforcement Agency to launch Belviq.
Belviq Gains FDA Approval For Weight Loss, But DEA Review Will Delay Launch
With a July 17 user fee date, Vivus’ obesity drug Qnexa could beat Arena Pharmaceuticals’ Belviq to the marketplace as lorcaserin awaits controlled substance scheduling by the Drug Enforcement Agency.
Arena Scores Hefty Obesity Drug Deal With Eisai Ahead Of PDUFA Date
In addition to upfront and milestone payments, deal also includes effective royalties above 30 percent of annual net sales.